ClinicalTrials.gg
RecruitingNCT05735704SANGUINEUpdated Oct 15, 2026

Early Detection and Screening of Hematological Malignancies - SANGUINE

An observational study in Hematologic Malignancy, sponsored by JaxBio Ltd. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by JaxBio Ltd · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hematologic Neoplasms with a site in Czechia — 7 open to participants now, 8 under way, 3 of them phase 3. Hematologic Neoplasms · Czechia.

Started
2023
with 1 other
Observational
Only one
of the 15
Registered
11th of 15
by date
Lead sponsor
1 of 15
JaxBio Ltd

Among the 15 studies in Hematologic Neoplasms with a site in Czechia, this one is one of 2 that started in 2023, is the only observational one, and was the 11th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

7 of the 15 studies in Hematologic Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hematologic Neoplasms with a site in Czechia, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.

*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included

Read the detailed description

Subjects will be screened for eligibility and then, after signing an Informed Consent Form, the first peripheral blood sample will be obtained.

Periodical blood samples will be obtained from the participants. Relapse patients will have their retrospective blood samples analyzed to identify early signs of disease.

The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS, and control subjects with no malignant disease.

In the second stage, at least 250 patients with MM 250 patients with NHL, at least 100 patients with each of the remaining hematological malignancies mentioned above, and control subjects with no malignant disease will be tested. Out of these patients, AML, lymphoma and MM patients will be followed up at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored in the clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment, and blood collection can begin in the first stage of the trial, to allow a maximum follow-up period, as part of the study, and to meet the recruitment goals.

The last stage consists of the screening of a larger group of subjects at risk of developing MM / lymphoproliferative disorder. This stage will include 400 elderly patients (>65 years old) and 500 first-degree relatives of patients (and in particular siblings). The screening, enrollment, and sample collection can begin in the first stage of the trial, to allow a maximum period for at-risk subjects cohort to meet the recruitment goals.

In all stages, the age and sex-matched subgroups will be considered and matched.

During the follow-up period, demographic and baseline parameters including sex, age, race, height and weight, medical history, smoking status, details of initial diagnosis and treatment history, concomitant medications as well as adverse events (AEs) of special interest, (serious) AEs related to study procedures, treatment for the disease, disease response and survival status will be collected (as applicable).

03

Conditions studied

  • Hematologic Malignancy

Keywords

  • Multiple myeloma
  • Pre-MM conditions
  • Hodgkin Lymphoma
  • Non-Hodgkin aggressive lymphoma
  • High Grade Lymphoma
  • Follicular Lymphoma
  • Marginal zone lymphoma
  • Acute Myeloid Leukemia
  • Myelodysplastic syndrome
  • Diffuse large B cell lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult subjects with hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), non-Hodgkin aggressive lymphoma NHL [diffuse large B cell lymphoma (DLBCL), FL, MZL, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria for all study populations:

  1. Male and female subjects ≥18 years of age
  2. Ability to understand and willingness to sign a written document.

For Patients with hematological :

1. Patients who have been diagnosed, have , and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS that did not yet undergo any treatment.

NOTE:

Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, who were treated for their primary disease (FL/MZL/MDS/MPN) before study enrollment, are eligible.

For subjects at risk for developing the investigated hematological malignancies:

  1. First-degree relatives; AND /OR
  2. Elderly subjects ≥ 65 years of age.

Exclusion criteria

Exclusion Criteria:

  1. Patients/subjects with current co-diagnosis of another type of cancer;
  2. Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection;
  3. Patients with a diagnosis of acute promyelocytic leukemia (APL)
  4. Patients/subjects with active inflammatory disease that requires treatment with / immunomodulation agents;
  5. Patients/subjects with known (HIV) positive;
  6. Patients/subjects with known active Hepatitis A/B/C or past ;
  7. Subjects that are likely to be noncompliant with the protocol, or felt to be unsuitable by the investigator for any other reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with Hematological Malignancies - Discovery stage

    The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, FL, MZL, AML, MDS. NOTE: Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, that were treated for their primary disease (FL/MZL/MDS/MPN) prior to study enrollment, are eligible. Patients with a diagnosis of acute promyelocytic leukemia (APL) will not be included. For patients, it is expected, after signing the informed consent, that the serial samplings will be performed during the disease follow-up according to the standard clinical practice and/or recommended schedule and disease assessment plan.

    Diagnostic Test: Blood sampling for HemaChip screening/diagnostic testing

  • Patients with Hematological Malignancies - Second stage

    In the second stage, at least 250 patients with MM, 250 patients with NHL, and at least 100 patients with each of the remaining hematological malignancies mentioned above will be tested. Out of these patients, AML, lymphoma, and MM patients will be followed up on at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored at clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment, and sample collection can begin in the first stage of the trial, to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.

    Diagnostic Test: Blood sampling for HemaChip screening/diagnostic testing

  • Subjects at risk of developing MM / lymphoproliferative disorder - Third stage

    The last stage consists of screening of a larger group of subjects at risk of developing MM / lymphoproliferative disorder. This stage will include 400 elderly patients (\>65 years old) and 500 first-degree relatives of patients (and in particular siblings). The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to meet the recruitment goals.

    Diagnostic Test: Blood sampling for HemaChip screening/diagnostic testing

  • Control subjects with no malignant disease- Discovery stage

    Control subjects with no malignant disease that serve as controls are expected to donate blood a single time. Following this donation, their participation will end.

    Diagnostic Test: Blood sampling for HemaChip screening/diagnostic testing

Interventions

  • Diagnostic testBlood sampling for HemaChip screening/diagnostic testing

    Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA, and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules. Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house. Years 2-3: Throughout the second phase of the project, a custom-targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.

    Also known as: HemaChip

06

What researchers measure

Primary outcomes

  1. Biomarker discovery

    define a set of differential epigenetic biomarkers that uniquely identify the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, HGL, FL and MZL transformed to large cell lymphoma), FL, MZL, de novo AML, secondary AML, MDS and healthy subjects.

    Time frame: 36 month

  2. Validation of Hemachip

    Validating the discovery platform (HemaChip) as a diagnostic tool for various blood cancers.

    Time frame: 36 month

  3. Early detection for hematological malignancies

    Towards early detection - Patients, at risk of relapse tested periodically to evaluate early detection capability of the HemaChip.

    Time frame: 36 month

  4. population screening for hematological malignancies

    Towards population screening - evaluate the sensitivity and specificity for screening in populations at risk for developing the investigated cancers: (i) elderly (\>65 years old) at high risk to develop MM; (ii) first degree relatives of the conditions described above.

    Time frame: 36 month

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 48 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2026 → Jan 2027 and completion Jan 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 21, 2023
StartActual
Jan 30, 2023
Primary completionEst.
Jan 31, 2027was Jan 2026
CompletionEst.
Jan 31, 2027was Jan 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • National and Kapodistrian University of Athens (NKUA) · Athens, Greece
Show 1 removed
  • National and Kapodistrian University of Athens (NKUA) · Atene, Greece
Oct 15, 2026
Primary completion
Jan 31, 2026→Jan 31, 2027
Oct 15, 2026
Study completion
Jan 31, 2026→Jan 31, 2027
Oct 15, 2026
Sponsor
Collaborators added: PredictBy Research and Consulting, S.L·National and Kapodistrian University of Athens; collaborators removed: PREDICTBY RESEARCH AND CONSULTING S.L.·National Kapodistrian University of Athens
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • National and Kapodistrian University of Athens (NKUA) · Athens, Greece
    Show 1 removed
    • National and Kapodistrian University of Athens (NKUA) · Atene, Greece
    Primary completion Jan 31, 2026→Jan 31, 2027
    Study completion Jan 31, 2026→Jan 31, 2027
    Sponsor Collaborators added: PredictBy Research and Consulting, S.L·National and Kapodistrian University of Athens; collaborators removed: PREDICTBY RESEARCH AND CONSULTING S.L.·National Kapodistrian University of Athens
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05735704
Lead sponsor
JaxBio Ltd
Collaborators
Tel Aviv University, FORSCHUNGSZENTRUM FUR MEDIZINTECHNIK UND BIOTECHNOLOGIE, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palaky University Olomouc, Vilnius University Hospital Santaros Klinikos, PredictBy Research and Consulting, S.L, National and Kapodistrian University of Athens, Tel-Aviv Sourasky Medical Center, UAB ORIENTOS, EUROPEAN CANCER ORGANISATION, Predict * By, JaxBio Technologies
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jan 30, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Helena Grinberg-Rashi, PhD
Contact
lenagrin@gmail.com
+31615636666
Yael Michaeli, PhD
Contact
yaelmi@jaxbio.com
Yuval Prof. Ebenstein, PhD
study chair · Tel Aviv University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion